Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2009

View Archived Issues

Abbott presents business highlights of first quarter

Study provides proof-of-concept of ChronVac vaccination for hepatitis C

Data backing clinical investigation of ANA-773 in hepatitis C presented

Janssen describes novel inhibitors of MDM2 and p53 interaction

Novel heat shock protein 90 inhibitors claimed by Vernalis for cancer treatment

Santen claims glucocorticoid receptor agonists for ocular inflammatory conditions

Alkylsulfone derivatives claimed by Daiichi Sankyo for the treatment of Alzheimer's disease

Taisho presents novel heterocyclic compounds for the treatment of pain

Novel inhibitor of p21-activated kinase disclosed by Pfizer with potential use as anticancer agent

Phase I data show responses in one-third of solid cancer patients given MKC-1106-PP immunotherapy

NanoBio initiates FDA approved adjuvanted intranasal influenza vaccine trial

FDA issues complete response to Discovery Labs regarding Surfaxin NDA in RDS

Galapagos and Opsona Therapeutics enter drug discovery collaboration

Isotechnika reports 12-month follow-up data from phase IIb PROMISE trial

Merck & Co., Medarex and MBL sign exclusive agreement

Novel humanized antibody with in vivo antitumor activity developed by Epitomics

Dendreon begins phase I trial of D-3263 in advanced cancer

EMD Serono identifies new pyridazinone c-MET kinase inhibitors

Circassia's initiates phase II ToleroMune trial in asthma patients

Melanin-concentrating hormone system may play role in addiction

Sanofi pasteur initiates clinical studies tetravalent dengue vaccine in Singapore and Vietnam

QRxPharma successfully completes phase III pilot study of MoxDuo IR

Health Canada approves Photocure's Metvix in combination with Aktilite for AK and sBCC

Alkermes presents update on the clinical development of Vivitrol

ImQuest and Arisyn receive phase I SBIR grant from NIH to develop HCV inhibitor

Welichem begins IND-enabling toxicology studies for WBI-1001

Transave completes enrollment in Arikace phase II bronchiectasis study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.